NCT05699226 Amplitude Titration to Improve ECT Clinical Outcomes
| NCT ID | NCT05699226 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of New Mexico |
| Condition | Depression |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2023-09-14 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2023-09-14 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A randomized controlled trial will compare hippocampal neuroplasticity, antidepressant, and cognitive outcomes between individualized amplitude and fixed 800 mA amplitude ECT in older depressed subjects (n = 25 per group, n = 50 total). Relative to fixed 800 mA ECT: H1: Individualized amplitude arm will have improved RUL antidepressant outcome (IDS-C30 response rates and reduced BT electrode placement switch at V2). H2: Individualized amplitude arm will have improved cognitive outcomes (DKEFS-Verbal Fluency
Eligibility Criteria
Inclusion Criteria: * Diagnosis of major depressive disorder or bipolar II * Clinical indications for ECT with right unilateral electrode placement Exclusion Criteria: * Defined neurological or neurodegenerative disorder (e.g., traumatic brain injury, epilepsy, Alzheimer's disease) * Other psychiatric conditions (e.g., schizophrenia, bipolar I disorder) * Current drug or alcohol use disorder (except for nicotine) * Contraindications to MRI.
Contact & Investigator
Chris Abbott, MD
PRINCIPAL INVESTIGATOR
University of New Mexico
Frequently Asked Questions
Who can join the NCT05699226 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Depression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05699226 currently recruiting?
Yes, NCT05699226 is actively recruiting participants. Contact the research team at cabbott@salud.unm.edu for enrollment information.
Where is the NCT05699226 trial being conducted?
This trial is being conducted at Albuquerque, United States.
Who is sponsoring the NCT05699226 clinical trial?
NCT05699226 is sponsored by University of New Mexico. The principal investigator is Chris Abbott, MD at University of New Mexico. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.